New potential treatment for aggressive types of childhood cancer

[PRESS RELEASE 2017-07-11] A combination of substances that impacts chemical modifications in the DNA of tumours and triggers the tumours to differentiate into harmless nerve cells could represent a new method of treating aggressive forms of neuroblastoma. The new method has been proposed by researchers at Karolinska Institutet, after studies using mice showed that the combination treatment resulted in a significant suppression in tumour growth. The study, published in PNAS, also questions a hypothesis within the research field that could result in potentially harmful wrong treatment of children with neuroblastoma.

Neuroblastoma affects the peripheral nervous system in children and is a tumour disease with different facets. A number of these tumours disappear naturally and others respond well to the treatment available. There are however some types of neuroblastoma that are very aggressive and, in many cases, do not respond to treatment. Mortality among these high-risk patients is high and there is therefore a substantial requirement for new and efficient methods of treatment. 

During the study, the researchers treated mice with the substance AZA, which blocks and eliminates methyl groups from the DNA of cancer cells, aiming to activate genes that fight the origins of neuroblastoma. AZA was then combined with treatment with retinoic acid (RA), a substance that has the capacity to make certain tumour cells differentiate, mature, into harmless nerve cells. 

Neither AZA nor RA could individually suppress the growth of high-risk tumours, but the combination treatment resulted in a significant suppression in tumour growth in the mice. The treatment induced expression of a factor called HIF2α, why the researchers also tested a combination with a HIF2α inhibitor. Such inhibitors have been proposed as an alternative treatment for neuroblastoma as the HIF2α protein has previously been described as being coupled to more aggressive forms of neuroblastoma. HIF2α inhibitor are currently being subject to clinical trials for treatment of other tumour diseases. 

“Interestingly, it emerged that the effect of our combination treatment with AZA and RA was, in fact, counteracted by the HIF2α inhibitor. Moreover, analyses of large volumes of patient data show that HIF2α is not coupled to aggressive types of neuroblastoma, but can be linked to a lower risk and improved survival for patients,” explains Johan Holmberg, researcher at the Ludwig Institute for Cancer Research and the Department of Cell and Molecular Biology at Karolinska Institutet. 

The role played by the HIF2α inhibitors requires further study before they can be used to treat neuroblastoma patients,” confirm the researchers. 

“In addition to demonstrating the effect of a new potential combination treatment, our study questions a hypothesis that may result in potentially harmful wrong treatment of children with neuroblastoma. The study could therefore be of importance for future clinical applications,” says Johan Holmberg. 

The research has been financed by StratCan, the Swedish Cancer Society, the Swedish Childhood Cancer Foundation, the Swedish Research Council, the Ludwig Institute for Cancer Research and the Knut and Alice Wallenberg Foundation.  

Publications: “Combined epigenetic and differentiation based treatment inhibits 

neuroblastoma tumor growth and links HIF2α to tumor suppression”. Isabelle Westerlund, Yao Shi, Konstantinos Toskas, Stuart M Fell, Shuijie Li, Olga Surova, Erik Södersten, Per Kogner, Ulrika Nyman, Susanne Schlisio & Johan Holmberg. Proceedings of the National Academy of Sciences (PNAS), online 10 July 2017. 

Johan Holmberg, researcher

The Department of Cell and Molecular Biology, Karolinska Institutet

The Ludwig Institute of Cancer Research

Tel: +46 (0)72-221 27 02


Karolinska Institutet is one of the world’s leading medical universities. Its vision is to significantly contribute to the improvement of human health. Karolinska Institutet accounts for the single largest share of all academic medical research conducted in Sweden and offers the country’s broadest range of education in medicine and health sciences. The Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine.


About Us

KAROLINSKA INSTITUTET PRESS OFFICE Opening hours: Monday–Friday 8–20, CET, Weekends 9–17, CETClosed 22 December–26 December and 29 December– 1 January Opening hours 27 December–6 January: 9–17 Karolinska Institutet – a medical university